Tamsulosin –– modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia

Author： van Dijk Marleen M   de la Rosette Jean JMCH   Michel Martin C  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.3, Iss.2, 2006-03, pp. : 237-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: Combined Treatment with Fesoterodine Fumarate Extended-Release and Tamsulosin - A Prospective Study

By  

Urologia Internationalis, Vol. 90, Iss. 2, 2012-12 ,pp. : 156-160

Karger

Access to resources Recommend Favorite

Comparison of Tamsulosin Plus Serenoa Repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label Study

By  

Urologia Internationalis, Vol. 94, Iss. 2, 2015-0 ,pp. : 187-193

Karger

Access to resources Recommend Favorite

Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract

By Stevens H. N. E   Speakman M.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2323-2328

Informa Healthcare

Access to resources Recommend Favorite

Benign Prostatic Hyperplasia: Diagnosis and Treatment

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 46, Iss. 9, 1998-09 ,pp. : 1163-1165

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting

By Flannery Michael T.   Ramsdell Joe   Ranhosky Alan   Davidai Giora   Ruoff Gary  

Current Medical Research and Opinion, Vol. 22, Iss. 4, 2006-04 ,pp. : 721-730

Informa Healthcare

Access to resources Recommend Favorite